Possis takes more powerful clot-removing catheter to the US:
This article was originally published in Clinica
Executive Summary
Possis Medical has released for sale in the US a version of its AngioJet thrombectomy catheter that can provide over twice the clot-removing power of its 4 French XMI and previous Spiroflex catheters. The device, called Spiroflex VG, is also the first AngioJet catheter of its size to be offered in a rapid exchange platform. It is available in the US for peripheral use only, though the Minneapolis, Minnesota firm plans to submit to the FDA a marketing application for coronary use in the coming weeks. Elsewhere, European CE- mark approval for the coronary and peripheral indications are pending.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.